Smear-positive tuberculosis (TB) is a global public health issue. Standard treatment regimens have medication resistance and extensive treatment duration. Due to its immunomodulatory and antiinflammatory properties, L-arginine may be an adjuvant therapy for TB. This study examined Larginine as an adjuvant medication in smear-positive TB patients. From December 2020 to June 2021, a tertiary care hospital in Mathura, K.M Medical College & Hospital, conducted a randomised controlled experiment. 150 patients were randomly randomised to L-arginine and 150 to placebo and evaluated for clinical and biochemical data. Adding L-arginine to anti-TB medication considerably improved clinical outcomes. In conclusion, L-arginine supplementation may be an effective adjuvant therapy for smear-positive TB patients, increasing treatment outcomes, constitutional symptoms, CRP, and cough. Further research is needed to validate these findings and evaluate L-arginine as a TB treatment supplement.

.